
-
Fortress Biotech NasdaqCM:FBIO Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Location: 1111 Kane Concourse, Bay Harbor Islands, FL, 33154, United States | Website: https://www.fortressbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
50.77M
Cash
91.34M
Avg Qtr Burn
-18.59M
Short % of Float
15.97%
Insider Ownership
21.11%
Institutional Own.
16.32%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CUTX-101 (Copper Histidinate) Details Menkes Disease , Blood cancer Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
CAEL-101 Details Amyloid light chain amyloidosis (Mayo Stage IIIa & Mayo Stage IIIb) | Phase 3 Data readout | |
Triplex Details Cytomegalovirus (CMV) | Phase 2 Data readout | |
Triplex Details Cytomegalovirus (CMV) | Phase 2 Data readout | |
Triplex Details Co-infected w/ Cytomegalovirus (CMV) and Human immunodeficiency virus (HIV) | Phase 2 Data readout | |
Triplex Details Cytomegalovirus (CMV) control in pediatric patients | Phase 1/2 Data readout | |
Dotinurad Details Chronic refractory gout | Phase 1b Update | |
Triplex + Allogeneic CMV-Specific CD19-CAR T Cells Details Acute lymphoblastic leukemia | Phase 1 Data readout | |
Triplex + bi-specific CMV/CD19 CAR T cell therapy Details Non-Hodgkin lymphoma | Phase 1 Data readout | |
Triplex + CMV-Specific CD19-CAR T-cells Details Non-Hodgkin lymphoma | Phase 1 Data readout | |
CEVA-101 Details Traumatic brain injury | Failed Discontinued |